›Portfolio Companies

Past, Present and Future Leaders

InterWest is proud and privileged to partner with visionary management teams who are shaping the future of Information Technology and Healthcare. The companies they have started are vital parts of the portfolio of industry-leading startups that InterWest has helped over the last four decades.

Our Companies

Early stage IT and Healthcare Investing

Trius Therapeutics Gains Membership in the Russell 2000® Index

latestnews

Trius Therapeutics Gains Membership in the Russell 2000® Index Jun 2011

Marketo Support Investment Ensures World-Class Service to Meet Demand of Fast-Growing EMEA Region

SAN DIEGO — Trius Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections, today announced that the Company was added to the Russell 2000(R) Index at the close of market on June 24, 2011 as part of the annual reconstitution of Russell indexes.

The Russell 2000(R) Index measures the performance of the small-cap segment of the U.S. equity universe. The Russell 2000(R) Index is a subset of the Russell 3000(R) Index representing approximately 8% of the total market capitalization of that index. Members of the Russell 2000(R) Index are also included in the Russell Global Index. These indexes are reconstituted annually in June and are widely used by investment managers and institutional investors for index funds and as benchmarks for passive and active investment strategies.
About Trius Therapeutics

Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. The company's lead investigational drug, torezolid phosphate, is an IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of acute bacterial skin and skin structure infections (ABSSSI), the first such trial to be initiated under a Special Protocol Assessment (SPA). In addition to the company's torezolid phosphate clinical program, it is currently conducting three preclinical programs using its proprietary discovery platform to develop antibiotics to treat infections caused by gram-negative bacteria. For more information, visit www.triusrx.com.

Portfolio Press Releases

About InterWest

Facebook Google+ Twitter Email LinkedIn Share